2528-01-0

Basic information

• Product Name: 5-Bromo-3-methyl-2-furancarboxylic acid methyl ester
• Synonyms: 5-Bromo-3-methyl-2-furancarboxylic acid methyl ester;Methyl 5-Bromo-3-Methylfuran-2-Carboxylate;Methyl 5-Bromo-3-Methylfuran-2-Carboxylate(WXC03034)
• CAS NO: 2528-01-0
• Molecular Formula: C₇H₇BrO₃
• Molecular Weight: 219.03
• Mol File: 2528-01-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 236.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.536±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 5-Bromo-3-methyl-2-furancarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-3-methyl-2-furancarboxylic acid methyl ester(2528-01-0)
• EPA Substance Registry System: 5-Bromo-3-methyl-2-furancarboxylic acid methyl ester(2528-01-0)

Safety Data

• Hazardous Substances Data: 2528-01-0(Hazardous Substances Data)

Upstream product

• 6141-57-7 methyl 3-methylfuran-2-carboxylate 
• 99183-76-3 methyl 5,5-dimethoxy-3-methyl-2,3-epoxypentanoate 
• 5436-21-5 acetylacetaldehyde dimethyl acetal 

Downstream Products

• 1333376-27-4 C₁₅H₁₆O₃ 
• 1333376-29-6 C₂₂H₂₃NO₂ 
• 1333376-28-5 C₁₄H₁₄O₃ 
• 952710-73-5 3-methyl-5-(4-trifluoromethyl-phenyl)-furan-2-carboxylic acid methyl ester 
• 1221184-17-3 methyl 5-(4-chlorophenyl)-3-methylfuran-2-carboxylate 
• 78259-61-7 2-(α-hydroxybenzyl)-4-methylfuran 
• 53492-34-5 pleraplysillin-2 

Relevant articles and documents

Synthetic studies on pseudolaric acid B: Enantioselective synthesis of C4,C10-di-epi-trans-fused [5-7]-bicyclic skeleton

Studies on the synthesis of antifungal and anticancer natural product, pseudolaric acid B, have led to the enantioselective synthesis of di-epi-trans-fused [5–7]-bicyclic core skeleton. The synthesis was achieved in 10 linear steps, which features the Sharpless asymmetric epoxidation, cyanide-opening reaction of epoxide, and intramolecular [5 + 2] cycloaddition reaction as the key transformations. The stereochemistry was determined by the X-ray crystallographic analysis.

SAR analysis of innovative selective small molecule antagonists of sphingosine-1-phosphate 4 (S1P4) receptor

Recent evidence suggests an innovative application of chemical modulators targeting the S1P4 receptor as novel mechanism-based drugs for the treatment of influenza virus infection. Modulation of the S1P4 receptor may also represent an alternative therapeutic approach for clinical conditions where reactive thrombocytosis is an undesired effect or increased megakaryopoiesis is required. With the exception of our recent research program disclosure, we are not aware of any selective S1P4 antagonists reported in the literature to date. Herein, we describe complementary structure-activity relationships (SAR) of the high-throughput screening (HTS)-derived hit 5-(2,5-dichlorophenyl)-N-(2,6-dimethylphenyl)furan-2- carboxamide and its 2,5-dimethylphenyl analog. Systematic structural modifications of the furan ring showed that both steric and electronic factors in this region have a significant impact on the potency. The furan moiety was successfully replaced with a thiophene or phenyl ring maintaining potency in the low nanomolar range and high selectivity against the other S1P receptor subtypes. By expanding the molecular diversity within the hit-derived class, our SAR study provides innovative small molecule potent and selective S1P 4 antagonists suitable for in vivo pharmacological validation of the target receptor.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is -O- and the like; R4 is a hydrogen atom and the like; R5 and R6 are each independently a hydrogen atom and the like; R1 is an optionally substituted hydrocarbon group and the like; R2 is a hydrogen atom and the like; and R3 is -(CH2)3-COOH and the like, or a salt thereof.